ReviewFrontiers in immunology2025
Apoptotic extracellular vesicles: emerging biomarkers for cancer and neurodegenerative disease diagnostics.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new subclass of extracellular vesicles formed on terminal apoptosis, apoptotic extracellular vesicles (ApoEVs), has been found to be potential markers for disease diagnosis, prognosis, and monitoring of treatment. Highlighting their role in neurological disorders and cancer as diagnostic markers, this review aims to present a new paradigm of ApoEV classification based on their biogenic process, cargo composition, and functional attributes. The heterogenous molecular content of such membrane-bound vesicles-like proteins, lipids, DNA, and RNA produces unique fingerprints reflective of the pathologic and physiological status of their parent cells. We critically examine the clinical significance, specificity, and sensitivity of current technological advancements in identifying and fractionating ApoEV through methodologies like flow cytometry, imaging processes, and molecular analysis. The prognostic and diagnostic potential of ApoEVs in cancer and neurological disease is the specific focus of this review. We address conflicting evidence, discuss controversy in the field, and contrast ApoEV-based methods with traditional biomarkers. We discuss the challenges of isolating, detecting, and validating ApoEVs and provide a standardized diagnostic procedure for clinical application. Lastly, we outline the next-generation research directions such as AI-assisted ApoEV analysis, emerging biosensor technologies, and ApoEV platforms for the specific purpose of application in personalized medicine. Finally, this thorough review critically evaluates the biological and technical hurdles which should be addressed for successful clinical translation, and the untapped potential of ApoEVs as non-invasive diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.